Chubb Q2 2026 Earnings Analysis

Philip Morris International Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: INCOME (https://betafinch.com/groups/INCOME) [https://betafinch.com/groups/INCOME)] ────────── Welcome to Beta Finch, your AI-powered earnings breakdown of the biggest names in the market. Here's the script for PMI's Q2 2026 call. --- **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Philip Morris International's second quarter 2026 results — and there's a lot going on here, including a CFO transition. But first, the standard stuff: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. **JORDAN:** Right, and PMI gave us plenty to unpack. Let's start with the headline numbers, because they were strong. **ALEX:** Very strong. Organic net revenue growth of +8% for the quarter, operating income up +11%, and adjusted diluted EPS hit $2.20 — that's +14% currency-neutral, +15% in dollar terms. Quarterly net revenue crossed $11 billion for the first time ever. **JORDAN:** And this wasn't just a currency tailwind story either. Outgoing CFO Emmanuel Babeau flagged that about a third of the EPS beat came from a favorable tax-related currency effect tied to the Russian ruble, but two-thirds was real operating strength — better SG&A phasing and a surprisingly strong combustible business. **ALEX:** Let's talk about that smoke-free business first, because it's really the engine of this whole story. IQOS adjusted in-market sales volume grew +5% in the quarter — that sounds almost modest until you realize it includes two known headwinds: an excise tax hike in Japan and a flavor ban in Poland. **JORDAN:** Strip those out and IQOS growth was over 10% in Q2, north of 11% for the first half. That's the real underlying trend. IQOS also just cracked Kantar's list of top 100 most valuable global brands — pretty remarkable for a product that's only a decade old. **ALEX:** VEEV, their vapor brand, had an absolutely wild quarter — shipments up 55% in Q2, 72% for the half. Management says it's now the number one closed-pod brand in Europe and in global travel retail. **JORDAN:** Now let's get into the U.S., because this is where investors have been the most impatient. ZYN shipments grew 2% year-over-year to 2.9 billion pouches, and importantly, that's despite lapping an inventory tailwind from last year. Sequentially versus a rough Q1, U.S. net revenue was up 38%, gross profit up 46%. **ALEX:** The bigger story is the product lineup. They just launched ZYN Ultra — a lower-priced moist variant meant to close the gap with competitors — and they're bringing 1.5 and 8 milligram dry formats in Q3. Babeau was pretty clear-eyed that it's early days, just two weeks of data on Ultra, but the initial read and consumer feedback were encouraging. **JORDAN:** And there's a regulatory tailwind too — ZYN got Modified Risk Tobacco Product authorization on 20 SKUs, the only nicotine pouch product with that designation. That lets them actually market reduced-risk claims versus cigarettes, which is a real differentiator. **ALEX:** Here's the strategic pivot that stood out to me: management is choosing to step up U.S. investment hard in the second half — more marketing, a new brand campaign called "When It Clicks," expanded distribution — partly to build ZYN and partly to lay the groundwork for IQOS ILUMA's eventual U.S. launch, pending FDA action. **JORDAN:** Which is why, despite beating estimates two quarters in a row, PMI held its full-year guidance rather than raising it. An analyst from Goldman actually pushed on this directly, and Babeau basically confirmed: yes, the flat guidance reflects the decision to plow incremental profit back into U.S. investment rather than let it drop straight to the bottom line. **ALEX:** Let's touch on combustibles too, because cigarettes had a surprisingly strong quart This episode includes AI-generated content.

GE Vernova Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the numbers and the noise from corporate earnings calls and turn them into something you can actually digest. I'm Alex. JORDAN: And I'm Jordan. Before we dive in, quick disclaimer: ALEX: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: With that out of the way — Alex, today we're on GE Vernova, ticker GEV, Q2 2026. And this is one of those quarters where I read the numbers twice because they seemed almost too good. ALEX: Right, let's just start with the headline: orders came in at $24.2 billion for the quarter, up 88% year-over-year. That's a book-to-bill ratio of over 2x, meaning they're booking twice as much business as they're actually shipping and billing right now. JORDAN: Which tells you the backlog is just ballooning. And it did — total backlog hit $176 billion, up $13 billion sequentially. CEO Scott Strazik said they're on track for $200 billion by 2027. ALEX: The engine behind all this is really Gas Power. They signed 20 gigawatts of new orders and slot reservations this quarter alone, pushing their total gigawatts under contract from 100 to 116. And they're now saying they expect to hit at least 125 gigawatts by year-end. JORDAN: What stood out to me is the mix — more than half of that contracted capacity is for their big HA turbines, the ones expected to run baseload for decades. That's not speculative demand, that's utilities and data centers locking in power for the long haul. And notably, about 80% of that demand is still traditional customers, only 20% data centers — so despite all the AI hype, this isn't just a data center story. ALEX: Though the data center piece is growing fast too. Electrification booked $2.7 billion in data center orders this quarter, bringing the first-half total north of $5 billion — more than double all of 2025. JORDAN: Let's talk margins, because that's really the story underneath the story. Adjusted EBITDA grew 61% year-over-year to $1.2 billion, and margin expanded 340 basis points. First-half margins are up 360 basis points versus last year, even as lower-margin-mix equipment revenue grows faster than services. ALEX: And free cash flow — this is the number that jumped out at me — $5.1 billion generated in the quarter alone. Year to date they're at roughly $10 billion, which is already two and a half times what they did in all of 2025. JORDAN: A lot of that is working capital benefit from customer down payments on all those gas turbine slot reservations. It's real cash, but investors should understand some of that first-half strength is front-loaded — CFO Ken Parks was upfront that second-half free cash flow will be notably lower than the first half. ALEX: Which is why the full-year guidance raise is still notable in context. Revenue guidance moved up to $45.5 to $46.5 billion, and free cash flow guidance jumped from $6.5-$7.5 billion to $11.5-$12.5 billion. JORDAN: That's almost double the original free cash flow guide. EBITDA margin guidance held steady at 12-14% for the year. ALEX: Let's hit segment performance quickly. Power segment orders more than doubled, revenue up 14%, EBITDA margin expanded 320 basis points to 18.8%. Electrification was even more dramatic — orders up 66% to $6.3 billion, revenue up 68% on a reported basis, margin up 700 basis points to 18.4%. JORDAN: Wind is the laggard, as expected. Orders down 40%, mostly onshore weakness in North America tied to permitting delays and tariff uncertainty. EBITDA losses of $275 million this quarter, and they're still guiding to roughly $400 million in losses for the full year. Management's basically saying: we're managing what we can control there and waiting for pol This episode includes AI-generated content.

CME Group Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] ────────── **BETA FINCH — CME GROUP Q2 2026 EARNINGS BREAKDOWN** ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're digging into CME Group's second quarter 2026 results — and trust me, there is a LOT to unpack here beyond just the numbers. JORDAN: Yeah, this one's spicy. We've got record revenue, but the real story is CME going toe-to-toe with the entire perpetual futures narrative that's been dominating headlines. ALEX: Before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Solid. Okay, let's start with the numbers, because they're genuinely strong. ALEX: Right. Revenue came in at just over $1.7 billion, up 1% year-over-year — that's a record for a second quarter and the second-highest quarterly revenue in company history, only behind Q1 of this year. Average daily volume was 29.8 million contracts, the second-best Q2 ever, within 1% of last year's record. JORDAN: And the real headline for me is market data — $238 million in revenue, up 20% year-over-year. That's 33 consecutive quarters of year-over-year growth. Thirty-three! That's not a hot streak, that's a business model. ALEX: It's wild. And adjusted EPS came in at $2.99, up 1% from last year, with a 69.5% adjusted operating margin. For a company this size, that margin is just remarkable. JORDAN: They also returned $1.2 billion to shareholders in the quarter — $468 million in dividends, $695 million in buybacks. And CFO Lynne McGregor, who's stepping into a bigger strategic role, noted July is already tracking 18% ahead of last year. So momentum's not slowing down. ALEX: Okay, now let's get into the thing everyone on the call wanted to talk about — perpetual futures. Multiple analysts pressed CEO Terry Duffy on this, and he came out swinging. JORDAN: He really did. His argument, basically boiled down: perpetuals are functionally leveraged spot products dressed up as futures. No expiration date, funding rate resets, auto-liquidation mechanics — and he says none of that works for the institutional risk managers who make up 94% of CME's volume. ALEX: He had this great anecdote about calling the CEO of a major energy trading firm and asking — I think he said nineteen times — whether they wanted CME to list a perpetual oil contract. Answer: no, every time. They said they couldn't risk-manage their book with something that just tracks leveraged spot price. JORDAN: And on the crypto comparison — which is really the only apples-to-apples perpetuals data point that exists right now — CME's Tim McCourt laid out some pretty stark numbers. CME's doing $4.5 to $6.5 billion a day in crypto derivatives volume, versus about $270 million a day for a Bitcoin perpetual that a competitor, Kalshi, launched in July. Open interest gap was even bigger — $9-10 billion at CME versus $10 million for that perpetual product. ALEX: So the message is basically: "We could launch these tomorrow if there were real demand, but the demand just isn't showing up where it matters." JORDAN: Right, and Duffy was pretty direct that this isn't a defensive posture — CME says it has contract specs ready to go. It's a "we'll do it when it makes sense" stance, not a "we can't compete" stance. ALEX: Let's talk product pipeline, because there's a lot coming. Twenty-four-seven crypto futures trading launched this quarter. This weekend, round-the-clock gold trading goes live. Next week, Single Stock futures relaunch — this is CME's second attempt at that product after a failed joint venture back in 2000. JORDAN: Duffy's reasoning on timing there was interesting — he basically said the market has evolved, equity valuations are much higher now, and in This episode includes AI-generated content.

Chubb Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: BANKS (https://betafinch.com/groups/BANKS) [https://betafinch.com/groups/BANKS)] ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, bringing you the numbers and the narrative behind the headlines. I'm Alex. JORDAN: And I'm Jordan. Today we're digging into Chubb Limited's Q2 2026 results. ALEX: Before we get into it — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: Good disclaimer to lead with, especially for a name like Chubb where there's a lot of moving parts. Let's set the scene. ALEX: Big quarter for the property and casualty giant. Core operating earnings came in at $2.8 billion, or $7.26 per share — that's up 14.6% on the earnings side and 18.2% on EPS year-over-year. JORDAN: And tangible book value per share, which CEO Evan Greenberg calls their most important measure of shareholder wealth creation, was up 17.1% year-over-year. That's a real headline number for an insurer. ALEX: Underwriting was the star. P&C underwriting income was over $1.9 billion, up almost 19%, with a combined ratio of 83.8%. Strip out catastrophes and look at the current accident year, and it's 82.2%. JORDAN: For listeners who don't live in insurance-speak, combined ratio under 100 means they're making underwriting profit before you even count investment income. Anything in the low 80s is genuinely excellent. ALEX: Investment income was also a record — $1.88 billion, up more than 11%. Their invested asset base is now $175 billion, up from $161 billion a year ago. New money is going in at a 5.5% yield, well above their current 5.1% book yield. JORDAN: That reinvestment spread is a nice tailwind — every maturing bond gets replaced with something yielding more, so investment income keeps compounding almost on autopilot. ALEX: Now here's where it gets interesting. Growth wasn't uniform across the business, and Greenberg was pretty blunt about why. JORDAN: Right, global P&C premiums were up 3% — but strip out large account and E&S property, which they're intentionally shrinking, and it's actually 6.3%. He specifically called out that pricing in casualty lines is starting to lag loss cost inflation, which he pegged at 6 to 7% for primary casualty and 9.5 to 12% for excess casualty. ALEX: And he didn't hold back on competitors either — talked about newer players and MGAs writing business on terms that experienced underwriters walked away from decades ago. JORDAN: That's classic late-cycle soft market behavior. He also flagged London wholesale actively writing U.S. casualty again, which he said is "a movie we've seen before" — that's not a compliment. ALEX: Meanwhile, the parts of the business firing on all cylinders: international retail grew almost 12%, Latin America 15.6%, Asia 12%. North America middle market and small commercial grew almost 9%. And their high net worth personal lines business — the one differentiated, non-commodity business — grew 6% with 90% retention. JORDAN: That diversification story is really the thesis of the whole call. When a reporter pushed on why Chubb sounds so much more cautious than some peers, Greenberg's answer was essentially: I can't speak for anyone else, I call it as I see it, and the results speak for themselves. ALEX: There was also a fun exchange about reinsurance — an analyst asked if Chubb might buy a reinsurer to build scale there, and Greenberg's answer was just, quote, "it makes zero sense." Pretty definitive. JORDAN: Short and blunt — that's very on-brand for him this call. Another notable moment: someone asked about rising AI and token costs eating into the tech efficiency gains insurers have been promising. Greenberg said Chubb tracks its token costs in hard dollars and called them "a fraction, a minor fraction" relative to the efficien This episode includes AI-generated content.

Intuitive Surgical Q2 2026 Earnings Analysis

More earnings analysis: https://betafinch.com [https://betafinch.com] Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE) [https://betafinch.com/groups/HEALTHCARE)] ────────── ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Intuitive Surgical's second quarter 2026 results. Before we get going, I do need to say — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions. JORDAN: And with that out of the way, Alex, this was actually a pretty strong quarter for Intuitive on paper. ALEX: It was. Revenue up 19% to $2.89 billion, non-GAAP EPS up 28% to $2.80 a share, operating margin at 42%. Total procedures grew 16%, with da Vinci procedures up 15% and Ion — their lung biopsy platform — up a huge 36%. JORDAN: There's a wrinkle in that gross margin number though. It came in at 70%, but $36 million of that was a one-time tariff refund benefit. Strip that out and you're looking at 68.7%, which is still solid, but worth noting when you're comparing quarters. ALEX: Right, and they actually raised full-year gross margin guidance because of that — now 68% to 69%, up from 67.5% to 68.5%. But here's the part that got analysts' attention: U.S. da Vinci procedure growth moderated to 12%, down from 14% in Q1. JORDAN: Yeah, and CFO Jamie Samath was pretty direct about why. They're seeing signs that patients are deferring elective procedures, and they specifically flagged the expiration of ACA enhanced premium subsidies as a factor. Basically, when people's insurance costs go up or coverage gets murkier, they push off surgeries that can wait. ALEX: The CEO, Dave Rosa, made a point of saying the underlying disease burden hasn't changed — people aren't getting healthier, they're just delaying care. Which, if you're an investor, is either reassuring or a "wait and see," depending on how you read it. JORDAN: There's also the GLP-1 story continuing to play out — bariatric procedures in the U.S. declined high-single-digits this quarter as more patients manage weight through drugs like Ozempic instead of surgery. ALEX: Let's talk strategy, because there was a lot packed into this call. The big one: the Extended Use Program. Starting in early 2027, Intuitive plans to increase the number of uses allowed on a subset of their EndoWrist instruments, specifically targeting lower-cost, high-volume benign procedures. JORDAN: This is a classic Intuitive move — they did something similar back in 2020. The idea is: lower the cost per procedure for hospitals, which drives more adoption, which drives more scale. An analyst on the call, Travis Steed, tried to get them to size the financial impact — he was fishing for whether this repeats the roughly 7-point hit to instrument revenue per procedure they saw last time. ALEX: And management wouldn't bite. Jamie Samath said flat out they're not ready to quantify it and will give more detail next quarter. So that's a real overhang to watch heading into 2027 guidance. JORDAN: The other big theme was geographic. China remains genuinely tough — increased domestic robotic competition, pricing pressure, and a new centralized tender process the government is rolling out. Dave Rosa was careful to say it's not quite the same as the volume-based pricing programs we've seen hit other device makers, but it's clearly something to watch. ALEX: Japan, on the other hand, looked more encouraging. New reimbursement policies kicked in June 1st, and they already saw system placements jump — 25 systems in Japan this quarter versus 15 a year ago. JORDAN: And then there's da Vinci 5, which is really the growth engine right now. They placed 468 total da Vinci systems, 246 of those were da Vinci 5, including 114 dual-console setups. The installed base is over 1,700 systems and 15,000 surgeons trained on it already. ALEX: One thing that stood out to me in t This episode includes AI-generated content.